Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (BHC)
NYSE:BHC
RESEARCH TOOLSreports
BHC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.96 - $11.46
Previous Close$7.83
Volume991.97K
Average Volume (3M)2.20M
Market Cap
$2.63B
Enterprise Value$33.37B
Total Cash (Recent Filing)$1.18B
Total Debt (Recent Filing)$21.62B
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 01, 2025EPS Estimate
0.86Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding367,933,900
10 Day Avg. Volume1,408,549
30 Day Avg. Volume2,198,685
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.27
Price to Cash Flow (P/CF)1.10
P/FCF Ratio0.90
Enterprise Value/Market Cap12.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.88
Enterprise Value/Ebitda11.67
Forecast
1Y Price Target
$8.67Price Target Upside19.26% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Bausch Health Companies News
PremiumCompany Announcements
Bausch Health Announces Conditional Redemption of Senior Notes
PremiumCompany Announcements
Bausch Health Launches $4 Billion Note Offering to Restructure Debt
PremiumCompany Announcements
Bausch Health Launches $3.8 Billion Credit Facilities Syndication
PremiumCompany Announcements
Bausch Health: Navigating Market Risks Amid Uncertain Product Acceptance
PremiumCompany Announcements
Bausch Health Reports Strong 2024 Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Guidance And PerformanceBausch Health traded with strength, with its guidance exceeding consensus, showing a stronger than expected performance.
Revenue And SalesBausch & Lomb sales exceeded projections, indicating robust demand in this segment.
Bears Say
Corporate DivestitureLack of clarity around the timeline and execution of the BLCO divestiture adds to cautious outlook.
Litigation And Legal ChallengesBausch Health did not offer any updates on the timeline for the lawsuit regarding Norwich's generic Xifaxan, adding to the uncertainty.
Product ExclusivityConcerns persist over the high contribution of Xifaxan to growth, which faces loss of exclusivity by January 2028, raising questions about future growth drivers.
---
Ownership Overview
19.08% Insiders
3.99% Mutual Funds
42.73% Other Institutional Investors
29.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $3.96 and its highest was $11.46 in the past 12 months.
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $2.63B.
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Feb 19, 2025. The company reported $1.132 earnings per share for the quarter, missing the consensus estimate of $1.133 by >-$0.001.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is 0.86.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 367,933,900 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $1.132 in its last earnings report, missing expectations of $1.133. Following the earnings report the stock price went up 10.292%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Currently, no hedge funds are holding shares in BHC
---
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.67 (19.26% Upside)
$8.67 (19.26% Upside)
Blogger Sentiment
Bullish
BHC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.02%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
---
BHC Company Deck
---
BHC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Bausch Health demonstrated strong operational and financial performance in 2024, with consecutive quarters of revenue and EBITDA growth, significant cash flow generation, and strategic advancements in key segments. However, challenges such as foreign exchange impacts, legal proceedings, and declines in certain segments present areas of concern.Read More>---
BHC Revenue Breakdown
47.34% Bausch + Lomb
25.69% Salix
12.23% International
10.77% Diversified Products
3.96% Solta Medical
---
BHC Stock 12 Month Forecast
Average Price Target
$8.67
▲(19.26% Upside)
Technical Analysis
Best Analysts Covering BHC
1 Year
1 Year Success Rate
8/24 ratings generated profit
1 Year Average Return
-17.07%
reiterated a sell rating 5 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -17.07% per trade.
---